The US journal "Science" has named the development of the drug Lenacapavir as this year's "Breakthrough of the Year". The ...
Lenacapavir, a treatment administered subcutaneously every six months, is capable of preventing infection with very high ...
That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...
That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...
The drug lenacapavir, developed by Gilead Sciences, provides protection for half a year instead of one day and has performed extremely well in clinical trials.